Home » Stocks » SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. (SLS)

Stock Price: $2.71 USD 0.04 (1.50%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.87 +0.16 (5.90%) Oct 23, 5:55 PM

Stock Price Chart

Key Info

Market Cap 25.64M
Revenue (ttm) n/a
Net Income (ttm) -20.19M
Shares Out 9.46M
EPS (ttm) -4.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.71
Previous Close $2.67
Change ($) 0.04
Change (%) 1.50%
Day's Open 2.74
Day's Range 2.68 - 2.83
Day's Volume 66,617
52-Week Range 1.46 - 10.89

More Stats

Market Cap 25.64M
Enterprise Value 23.21M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 9.46M
Float 8.96M
EPS (basic) -3.55
EPS (diluted) -4.95
FCF / Share -2.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 419,268
Short Ratio 2.00
Short % of Float 4.68%
Beta 1.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.68
Revenue n/a
Operating Income -19.99M
Net Income -20.19M
Free Cash Flow -18.21M
Net Cash 2.43M
Net Cash / Share 0.26
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -54.24%
ROE -222.82%
ROIC -455.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(195.20% upside)
Low
8.00
Current: $2.71
High
8.00
Target: 8.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-20.04-31.09-23.04-16.51-34.22-43.90-28.49-21.20-12.49-16.63
Net Income-19.29-27.67-23.75-17.68-63.90-36.61-76.68-34.97-11.49-11.99
Shares Outstanding2.560.260.050.020.01-----
Earnings Per Share-10.92-157.72-522.00-933.00-12,346.24-9,195.92-25,502.55-16,801.68-9,600.96-20,102.01
Operating Cash Flow-17.64-30.42-10.99-11.85-48.16-42.87-28.93-20.97-14.67-10.26
Capital Expenditures-----0.15-0.06-0.32--0.05-0.11
Free Cash Flow-17.64-30.42-10.99-11.85-48.31-42.93-29.25-20.97-14.72-10.36
Cash & Equivalents7.385.4512.756.0530.1323.8547.9935.5911.546.91
Total Debt0.22-10.997.374.748.409.890.060.570.07
Net Cash / Debt7.165.451.76-1.3225.3915.4538.1035.5310.976.84
Assets16.6116.9233.536.4282.1480.4987.9854.9930.977.48
Liabilities10.5211.6731.4611.4268.6343.4382.0927.2320.865.05
Book Value6.095.252.07-5.0013.5137.065.8927.7610.112.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name SELLAS Life Sciences Group, Inc.
Country United States
Employees 5
CEO Angelos M. Stergiou

Stock Information

Ticker Symbol SLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SLS

Description

SELLAS Life Sciences Group, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S that is in Phase 2b clinical trials for the treatment of breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.